Milos Graonic, senior vice president, global leader of Nielsen BASES Pharmaceutical Practice, on how to mine patient data for forecasting insights
Todd Johnson of Kantar Health outlines how market research can be honed into reliable data to improve forecasts
Angelo DePalma explores how many pharma firms are focusing on improved molecules, or biobetters, to optimize existing portfolios and increase market share
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting
Angelo DePalma examines the commercial future of the biosimilars market
Angelo DePalma explores how drug firms can re-invent the pharma supply chain to add value to drug developers and benefit for patients
Carl Gerrard, Shire’s senior manager business analysis and forecasting, explains how forecasters can leverage company resources to optimize forecasts
Michael Turner, vice president, brand management practice, Campbell Alliance, on creating structured forecasts that account for unpredictability
Networking requires us to recognise that we all have something to offer
The NIH’s Undiagnosed Diseases Program (UDP) has so far discovered two new rare diseases
How online info helps to change opinions, even among physicians
Melonie Warfel, director, Life Sciences Industry Solutions, Pegasystems, on how to foster a culture of business transformation
How I learned to love the iPad a little bit less
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
Prasad Saraph, business partner at Bayer HealthCare, explains why forecasting must reflect an organization’s collective intelligence
Peter Mansell reports on how to balance complexity and predictability when forecasting for biologics
Angelo DePalma outlines the prospects for the global market for pain management pharmaceuticals and devices